New study aims to sharpen genetic testing for metastatic breast cancer

NCT ID NCT06706570

Recruiting now Diagnosis Sponsor: European Institute of Oncology Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study enrolls 100 people with metastatic, hormone receptor-positive, HER2-negative breast cancer to compare different genetic testing methods for detecting PIK3CA mutations. Researchers will check how well newer DNA sequencing techniques match up with standard PCR tests. The goal is to find the most reliable way to identify patients who might benefit from targeted therapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to more accurate and faster genetic testing for breast cancer, helping doctors choose the right targeted therapy for each patient.
What could go wrong: This is an observational study focused on comparing diagnostic methods, not testing a new treatment. It may not directly improve patient outcomes or survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER, METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER, METASTATIC

Contacts and locations

Locations

European Institute of Oncology
RECRUITING

Milan, MI, 20141, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.